Laws and Labels: A Regulatory View of Biosimilars
Now that the first biosimilar product has been approved by FDA, healthcare professionals need to get up to speed on the evolving rules and policies that will separate biosimilars from interchangeable biologics and branded products. Join healthcare legal expert Erika Lietzan for a webinar examining the latest from the FDA on labeling biosimilars, the scientific and legal differences between biosimilars and other products, and the potential impact on prescribing and dispensing practices.
You may also like:
Adverse drug reactions from antibiotic exposure occur in one out of every five patients, according to two large studies of patients in the community and hospitalized patients, respectively. The community study measured emerge...
The American Society of Automation in Pharmacy’s (ASAP) Midyear Conference brought more than 100 key technology executives together for three days of learning in Palm Beach, Florida. Thro...
Stay in the Know
Sign up to start receiving notifications via email of our upcoming webinars!